Merck 2008 Annual Report Download - page 86

Download and view the complete annual report

Please find page 86 of the 2008 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 153

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153

Acquisitions
At the end of 2007, we completed the acquisition of a 100% interest in Solvent Innova-
tion GmbH of Cologne, Germany, for a purchase price of € 2.0 million. The company,
which was consolidated for the first time as of January 1, 2008, is strengthening the
research activities of our Performance & Life Science Chemicals division in the field
of ionic liquids.
On February 29, 2008, Merck acquired a 100% interest in SeQuant AB of Umea,
Sweden, for € 6.9 million. This included transaction costs of € 0.1 million. The company
is strengthening the activities of our Performance & Life Science Chemicals division
in the field of chromatography. The company was consolidated for the first time on
March 1, 2008.
On June 30, 2008, Litec-LLL GmbH of Greifswald, Germany was acquired in full for
€ 5.6 million (including transaction costs of € 0.6 million). The company specializes in
research and development as well as production and marketing of ortho-silicate light-
ing materials. The acquisition of the company, which was founded in 2002, gives
Merck access to the business with light sources for LEDs. The company was consoli-
dated for the first time on July 1, 2008 and is part of the Liquid Crystals division.
On August 21 and 27, we increased our interest in the fully consolidated Indonesian
company PT Merck Tbk of Jakarta, Indonesia, by a total of 12.66% to 86.65%, for
€ 10.2 million.
On December 1, 2008, Merck acquired Bio-Fyt Pharma N.V. of Sint-Jans-Molenbeek,
Belgium, in full for € 30.0 million. Including the assumption of cash and transaction
costs of € 0.2 million, the total cost of the acquisition was € 32.6 million. The com-
pany, which is now part of the Consumer Health Care division, develops and markets
products for mobility, women's health and everyday health protection. The company
was consolidated for the first time on December 1, 2008.
72 Income Statement
73 Balance Sheet
74 Segment Reporting
CONSOLIDATED FINANCIAL STATEMENTS OF THE MERCK GROUP
76 Cash Flow Statement
77 Free Cash Flow
77 Statement of Recognized
Income and Expense
78 Statement of Changes
in Net Equity including
Minority Interest
79 Notes
81